Summit Therapeutics is trading 5.47% down now at $12.44, while the specific intraday trigger remains unclear.
- No confirmed company-specific announcement has been identified for August 24, 2026; the latest listed release remains the August 12 China approval of ivonescimab, rather than a new catalyst.
- The decline broadly coincides with the Nasdaq Composite down 0.60%.
- Recent coverage highlights ongoing clinical, regulatory, and spending risks.